Seeking Alpha

Tonix stock slides 10% on failed Phase 2 study for Long COVID drug

Tonix Pharmaceuticals (NASDAQ:TNXP) stock was down 10% in early trading Tuesday after the biotech announced that a Phase 2 trial for its drug candidate TNX-102 SL failed to meet its primary endpoint ...
Nasdaq

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate ...

SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...
Nasdaq

Ocugen Reports Positive Two-Year Safety and Efficacy Results for OCU400 in Phase 1/2 Clinical Trial for Retinitis Pigmentosa

OCU400 shows significant long-term improvements in visual function and mobility for retinitis pigmentosa patients, with a strong safety profile. Ocugen, Inc. announced positive results from its Phase ...
Seeking Alpha

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first ...